Notice of Availability of Administrative Supplements for Disseminating Evidence-Based Intervention Research Products
NCI is requesting applications for administrative supplements for NCI-funded cancer control intervention research R01, P01, P50, U01, and U19 grants. These supplements have been designed to provide 1-year funding to cancer control investigators whose intervention efficacy data have been analyzed and who are conducting peer-reviewed research (with an active NCI grant award) related to the intervention program proposed for dissemination.
The supplements will support R01, P01, P50, U01, and U19 award mechanisms.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=1980
Inquiries should be addressed to the NCI Program Director for the particular R01, P01, P50, U01, or U19 for which the supplement is being requested.
Inter-Institute Program for the Development of AIDS-Related Therapeutics
The Inter-Institute Program (IIP) for the Development of AIDS-Related Therapeutics is cosponsored by the National Institute of Allergy and Infectious Diseases and NCI. Investigators are invited to submit proposals to this therapeutics development program. The IIP is designed to help AIDS research investigators facilitate the preclinical development of: (1) therapies for the treatment of HIV disease, AIDS-associated malignancies, opportunistic infections, and tuberculosis associated with AIDS and (2) microbicide-based prevention strategies for HIV.
The IIP does not fund grants but instead provides IIP drug development resources.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=1981
Inquiries: Inter-Institute Program Coordinator, email@example.com